A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeutics.

Autor: Lietz CE; Boston University Chobanian & Avedisian School of Medicine, Boston, USA.; Center for Sarcoma and Connective Tissue Oncology, Department of Orthopedic Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Newman ET; Center for Sarcoma and Connective Tissue Oncology, Department of Orthopedic Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Kelly AD; Foundation Medicine, Cambridge, MA, USA., Xiang DH; Center for Sarcoma and Connective Tissue Oncology, Department of Orthopedic Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Zhang Z; Center for Sarcoma and Connective Tissue Oncology, Department of Orthopedic Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.; Department of Biomedical Engineering, Boston University, Boston, USA., Ramavenkat N; Center for Sarcoma and Connective Tissue Oncology, Department of Orthopedic Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Bowers JJ; Center for Sarcoma and Connective Tissue Oncology, Department of Orthopedic Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Lozano-Calderon SA; Center for Sarcoma and Connective Tissue Oncology, Department of Orthopedic Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Ebb DH; Division of Pediatric Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Raskin KA; Center for Sarcoma and Connective Tissue Oncology, Department of Orthopedic Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Cote GM; Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Choy E; Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Nielsen GP; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Vlachos IS; Harvard Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA., Haibe-Kains B; Princess Margaret Cancer Centre, University Health Network, Toronto M5G 1L7, Ontario, Canada.; Medical Biophysics, University of Toronto, Toronto M5G 2M9, Ontario, Canada.; Vector Institute for Artificial Intelligence, Toronto M5G 1L7, Ontario, Canada., Spentzos D; Center for Sarcoma and Connective Tissue Oncology, Department of Orthopedic Surgery, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

Publikováno v: MedRxiv : the preprint server for health sciences [medRxiv] 2024 Jun 20. Date of Electronic Publication: 2024 Jun 20.

MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma.

Autor: Lietz CE; Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Garbutt C; Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.; Illumina, Inc., San Diego, United States., Barry WT; Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States., Deshpande V; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Chen YL; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Lozano-Calderon SA; Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Wang Y; Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, United States.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, United States., Lawney B; Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, United States.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, United States., Ebb D; Pediatric Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Cote GM; Department of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Duan Z; Department of Orthopaedic Surgery, UCLA, Los Angeles, CA, United States., Hornicek FJ; Department of Orthopaedic Surgery, UCLA, Los Angeles, CA, United States., Choy E; Department of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Petur Nielsen G; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States., Haibe-Kains B; Department of Medical Biophysics, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada., Quackenbush J; Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, United States.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, United States., Spentzos D; Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. dspentzos@mgh.harvard.edu.

Publikováno v: Scientific reports [Sci Rep] 2020 Mar 10; Vol. 10 (1), pp. 4409. Date of Electronic Publication: 2020 Mar 10.